Brepocitinib tosylate is a small molecule commercialized by Roivant Sciences, with a leading Phase III program in Dermatomyositis. According to Globaldata, it is involved in 25 clinical trials, of which 22 were completed, 2 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Brepocitinib tosylate’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Brepocitinib tosylate is expected to reach an annual total of $273 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Brepocitinib tosylate Overview
Brepocitinib tosylate is under development for the treatment of moderate to severe hidradenitis suppurativa, dermatomyositis, non-infectious uveitis, posterior uveitis, panuveitis, intermediate uveitis. It is administered through the oral route as a tablet and by topical route as cream. It acts by targeting both JAK1 and TYK2 protein kinases.
It was also under development for the treatment of plaque psoriasis, mild to moderate atopic dermatitis (AD), Crohn's disease, psoriatic arthritis, cicatricial alopecia (CA), psoriasis, active non-segmental vitiligo, systemic lupus erythematosus and moderate to severe ulcerative colitis.
Roivant Sciences Overview
Roivant Sciences is a commercial-stage biopharmaceutical company. The company pipeline product candidates include VTAMA (tapinarof), RVT-3101, batoclimab, IMVT-1402, brepocitinib, namilumab and RVT-2001x. Roivant Sciences pipeline candidates’ indications are psoriasis, atopic dermatitis, ulcerative colitis, crohn’s disease, myasthenia gravis, thyroid eye disease, WAIHA, CIDP, graves’ disease, numerous indications, dermatomyositis, systemic lupus erythematosus, sarcoidosis and other indications. The company also utilizes its proprietary QUAISAR platform to gain critical project insights and engineer drug candidates with desired properties. It operates in Switzerland, Bermuda, Canada, the UK and the US. Roivant Sciences is headquartered in London, England, the UK.
The company reported revenues of (US Dollars) US$61.3 million for the fiscal year ended March 2023 (FY2023), an increase of 10.8% over FY2022. The operating loss of the company was US$1,146 million in FY2023, compared to an operating loss of US$1,280.1 million in FY2022. The net loss of the company was US$1,009 million in FY2023, compared to a net loss of US$845.3 million in FY2022.
The company reported revenues of US$37.1 million for the third quarter ended December 2023, an increase of 0.1% over the previous quarter.
For a complete picture of Brepocitinib tosylate’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
